海普瑞2022年报

(A joint stock company incorporated in the People’s Republic of China with limited liability)Stock Code 股份代號: 9989（於中華人民共和國註冊成立的股份有限公司）ANNUAL REPORT年度報告2022年度報告Annual Report 2022 Corporate Information 2公司資料Financial Highlights 5財務摘要Chairman’s Statement 6董事長致辭Management Discussion and Analysis 9管理層討論與分析Directors, Supervisors and Senior Management 29董事、監事及高級管理層Directors’ Report 35董事會報告Corporate Governance Report 61企業管治報告CONTENTS 目錄Independent Auditor’s Report 84獨立核數師報告Consolidated Statement of Profit or Loss 95綜合損益表Consolidated Statement of Comprehensive Income 96綜合全面收益表Consolidated Statement of Financial Position 97綜合財務狀況表Consolidated Statement of Changes in Equity 99綜合權益變動表Consolidated Statement of Cash Flows 101綜合現金流量表Notes to Financial Statements 105財務報表附註 SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. 深圳市海普瑞藥業集團股份有限公司 ANNUAL REPORT 2022 年度報告Corporate Information公司資料2Board of DirectorsExecutive DirectorsMr. Li Li (Chairman)Ms. Li Tan (Deputy General Manager)Mr. Shan Yu (General Manager)Mr. Zhang Bin (resigned on April 29, 2022)Independent Non-executive DirectorsDr. Lu ChuanMr. Chen JunfaMr. Wang ZhaohuiJoint Company SecretariesMr. Qian FengqiMs. Chan Sze Ting (ACG, HKACG)Authorized RepresentativesMr. Qian FengqiMs. Chan Sze TingSupervisorsMr. Zheng Zehui (Chairman)Ms. Tang HaijunMs. Su Jilan (Employee Supervisor)Strategy CommitteeMr. Li Li (Chairman)Ms. Li TanDr. Lu ChuanRemuneration and Evaluation CommitteeMr. Wang Zhaohui (Chairman)Mr. Chen JunfaMr. Li Li董事會執行董事李鋰先生（董事長）李坦女士（副總經理）單宇先生（總經理）張斌先生（於二零二二年四月二十九日辭任）獨立非執行董事呂川博士陳俊發先生王肇輝先生聯席公司秘書錢風奇先生陳詩婷女士（ACG, HKACG）授權代表錢風奇先生陳詩婷女士監事鄭澤輝先生（主席）唐海均女士蘇紀蘭女士（職工監事）戰略委員會李鋰先生（主席）李坦女士呂川博士薪酬與考核委員會王肇輝先生（主席）陳俊發先生李鋰先生 ANNUAL REPORT 2022 年度報告 SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. 深圳市海普瑞藥業集團股份有限公司Corporate Information公司資料3Audit CommitteeMr. Chen Junfa (Chairman)Dr. Lu ChuanMr. Wang ZhaohuiNomination CommitteeDr. Lu Chuan (Chairman)Mr. Li LiMr. Chen JunfaRegistered OfficeNo. 21 Langshan RoadNanshan District, ShenzhenPeople’s Republic of ChinaHeadquarters and Principal Place of Business in the PRCNo. 21 Langshan RoadNanshan District, ShenzhenPeople’s Republic of ChinaPrincipal Place of Business in Hong KongRoom 4724, 47th Floor, Sun Hung Kai Center30 Harbour Road, Wan ChaiHong KongPrincipal BanksChina Merchants Bank, Shenzhen BranchChina Merchants Bank TowerNo. 7088 Shennan BoulevardShenzhen, ChinaBank of China, Shenzhen Branch2022 Jianshe Road, Luohu DistrictShenzhen, ChinaThe Hongkong and Shanghai Banking Corporation Limited1 Queen’s Road CentralHong KongCompliance AdviserSomerley Capital Limited20/F, China Building29 Queen’s Road CentralHong Kong審計委員會陳俊發先生（主席）呂川博士王肇輝先生提名委員會呂川博士（主席）李鋰先生陳俊發先生註冊辦事處中華人民共和國深圳市南山區朗山路21號總部及中國主要營業地點中華人民共和國深圳市南山區朗山路21號香港主要營業地點香港灣仔港灣道30號新鴻基中心47樓4724室主要往來銀行招商銀行深圳分行中國深圳市深南大道7088號招商銀行大廈中國銀行深圳分行中國深圳羅湖區建設路2022號香港上海滙豐銀行有限公司香港皇后大道中1號合規顧問新百利融資有限公司香港皇后大道中29號華人行20樓 SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. 深圳市海普瑞藥業集團股份有限公司 ANNUAL REPORT 2022 年度報告Corporate Information公司資料4香港法律顧問安理國際律師事務所香港中環交易廣場三座9樓中國法律顧問北京中銀（深圳）律師事務所深圳市福田區深南大道2002號中廣核大廈北樓8層國際核數師安永會計師事務所執業會計師註冊公眾利益實體核數師香港鰂魚涌英皇道979號太古坊一座27樓境內核數師安永華明會計師事務所（特殊普通合夥）執業會計師中國北京巿東城區東長安街1號東方廣場安永大樓17層H股證券登記處卓佳證券登記有限公司香港夏愨道16號遠東金融中心17樓股票代碼A股：002399（深圳證券交易所）H股：9989（香港聯合交易所）公司網站www.hepalink.comHong Kong Legal AdviserAllen & Overy9/F, Three Exchange SquareCentralHong KongPRC Legal AdviserZhong Yin (Shenzhen) Law Firm8th Floor, North Building, China Guangdong Nuclear Power Building2002 Shennan Avenue, Futian DistrictShenzhenInternational AuditorErnst & YoungCertified Public AccountantsRegistered Public Interest Entity Auditor27th floor, One Taikoo Place979 King’s Road, Quarry BayHong KongDomestic AuditorErnst & Young Hua Ming (LLP)Certified Public AccountantsLevel 17, Ernst & Young TowerOriental Plaza, 1 East Chang An Avenue,Dongcheng DistrictBeijing, ChinaH Share RegistrarTricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt RoadHong KongStock CodeA Shares: 002399 (Shenzhen Stock Exchange)H Shares: 9989 (Hong Kong Stock Exchange)Website of the Companywww.hepalink.com ANNUAL REPORT 2022 年度報告 SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. 深圳市海普瑞藥業集團股份有限公司Financial Highlights財務摘要5Results of operations 經營業績RMB’000人民幣千元20182019202020212022二零一八年 二零一九年 二零二零年 二零二一年二零二二年 Revenue營業額4,799,8074,612,1055,315,6856,359,7867,151,039Profit before tax稅前利潤765,2071,315,2801,327,836222,264829,851Profit attributable to owners of the Company for the year年度本公司擁有人 應佔溢利640,1941,059,7001,024,210240,788727,077Basic earnings per share每股基本盈利0.510.850.760.160.50Asset information 資產狀況RMB’000人民幣千元20182019202020212022二零一八年 二零一九年 二零二零年 二零二二年二零二二年 Total assets資產總額13,844,278 15,351,947 19,025,895 19,108,17720,814,204Total liabilities負債總額7,567,9457,880,0737,336,9057,584,8628,406,565Equity attributable to shareholders of the Company歸屬於本公司股東權益6,099,6127,348,360 11,569,392 11,411,35412,310,915Share capital股本1,247,2021,247,2021,467,2961,467,2961,467,296Revenue 營業額RMB